Oral Abstract Session 01 - Global HIV Vaccine Enterprise

PROGRAM / TUESDAY
14
Program
13:30 – 14:45 Oral Abstract Session 11: BCEC Level 2,
Vaccine Immunogens / Delivery Ballroom East
Chairs: Harriet Robinson and Sallie Permar
13:30 – 13:45 HIV-1 Envelope Trimer Elicits Higher Neutralizing Antibody Responses OA11.01
Than Monomeric gp120
JM Kovacs, JP Nkolola, H Peng, A Cheung, J Perry, CA Miller, MS Seaman,
D Barouch, B Chen
13:45 – 14:00 Shaping Humoral Responses Against Mini-libraries of HIV Env Antigens via OA11.02
Lipid Nanoparticle Vaccine Delivery
MC Hanson, J Mata-Fink, W Abraham, KD Wittrup, DJ Irvine
14:00 – 14:15 Vaccine Responses to Conserved Regions of the HIV-1 Proteome Are OA11.03
Associated with an Increased Capacity to Inhibit Multiple Virus Isolates
Ex Vivo
A Ashraf, J Kopycinski, H Cheeseman, F Lala, J Czyzewska-Khan, A Spentzou,
DK Gill, M Keefer, J Excler, P Fast, P Hayes, JH Cox, J Gilmour
14:15 – 14:30 Antigen-specific T Lymphocyte Responses Elicited by a DNA – MVA HIV OA11.04
CN54gp140 Immunization Regime Are Significantly Altered by the TLR4
Adjuvant GLA
PF McKay, AV Cope, J Swales, S Joseph, M Esteban, R Tatoud, D Carter,
J Weber, RJ Shattock
14:30 – 14:45 Quality of T-cell Responses Versus Reduction in Viral Load: Results from an OA11.05 LB
Exploratory Phase II Clinical Study of Vacc-4x, a Therapeutic HIV Vaccine
K Ellefsen-Lavoie, J Rockstroh, R Pollard, G Pantaleo, D Podzamczer, D Asmuth,
J van Lunzen, K Arastéh, D Schürmann, B Peters, B Clotet, D Hardy, A Lazzarin,
J Gatell, MA Sommerfelt, I Baksaas, V Wendel-Hansen, B Sørensen
13:30 – 14:45 Oral Abstract Session 12: BCEC Level 2,
Vaccine Concepts – Vectors and Inserts Room 253 ABC
Chairs: Punnee Pitisuttithum and Karin Lore
13:30 – 13:45 DNA Vaccines Expressing Conserved Elements Provide Potent and Broad OA12.01
Immune Responses
GN Pavlakis, V Kulkarni, A Valentin, M Rosati, NY Sardesai, B Mothe,
C Brander, S LeGall, DB Weiner, M Rolland, JI Mullins, BK Felber
13:45 – 14:00 Reinventing the Nucleic Acid Vaccine with Self-amplifying RNA OA12.02
AJ Geall, GR Otten, A Hekele, W Bogers, H Oostermeijer, P Mooij,
K Gerrit, E Verschoor, K Banerjee, Y Cu, CW Beard, LA Brito, JB Ulmer,
CW Mandl, SW Barnett
14:00 – 14:15 Adenovirus Serotype 26 Utilizes CD46 as Primary Cellular Receptor and OA12.03
Only Transiently Activates T Lymphocytes Following Vaccination of
Rhesus Monkeys
H Li, EG Rhee, K Masek-Hammerman, JE Teigler, P Abbink, DH Barouch
AIDS Vaccine 2012
Tuesday, 11 September